sermorelincomparePeptides compared by molecule

Sources

Every document the pharmacological figures on this site rest on, with the author, the title as printed, where it appeared, the date printed on the document itself, the identifier that outlives the link, and the day we read it. The document behind a particular figure is also linked in the cell that prints it, on the matrix and on each head-to-head page: sermorelin vs ipamorelin and CJC-1295 vs sermorelin.

This list says what the figures are owed to. It does not say the site is fully sourced, and it would look identical on a site where one figure in five had a document behind it. What is still owed is counted beside it and marked, in visible text, wherever it appears.

The documents

8 documents are cited on this page, listed in the order the figures above rely on them. Each carries the date printed on the document itself, which is not the date it was read and not the date in its address.

  1. Esposito P, Barbero L, Caccia P, Caliceti P, D'Antonio M, Piquet G, Veronese FM. PEGylation of growth hormone-releasing hormone (GRF) analogues. Advanced Drug Delivery Reviews, volume 55, issue 10, pages 1279–1291.Document date: 2003-09-26. PMID 14499707, doi:10.1016/s0169-409x(03)00109-1. Read September 2026.
  2. Food and Drug Administration, Department of Health and Human Services. Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness. Federal Register, volume 78, number 42, pages 14095–14096, Notice.Document date: published 2013-03-04, signed 2013-02-26. 78 FR 14095, FR Doc. 2013-04827, Docket No. FDA-2012-P-1071. Read September 2026.
  3. Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, Ruchała M. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Frontiers in Endocrinology, volume 17, article 1822475.Document date: 2026-06-18. PMID 42395176, PMC13322892, doi:10.3389/fendo.2026.1822475. Read September 2026.
  4. Theratechnologies Inc., prescribing information approved by the Food and Drug Administration. EGRIFTA SV (tesamorelin) for injection, for subcutaneous use — full prescribing information. DailyMed structured product label, National Library of Medicine.Document date: label face date: Revised 03/2024; label version published 2026-07-31. SPL set id 3d783378-b02d-4f19-99dd-0fc91a042224, Initial U.S. Approval 2010. Read September 2026.
  5. Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. Journal of Pharmacology and Experimental Therapeutics, volume 329, issue 3, pages 1110–1116.Document date: 2009-06. PMID 19289567, doi:10.1124/jpet.108.149211. Read September 2026.
  6. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, volume 16, issue 9, pages 1412–1416.Document date: 1999-09. PMID 10496658, doi:10.1023/a:1018955126402. Read September 2026.
  7. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, volume 139, issue 5, pages 552–561.Document date: 1998-11. PMID 9849822, doi:10.1530/eje.0.1390552. Read September 2026.
  8. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism, volume 91, issue 3, pages 799–805.Document date: 2006-03. PMID 16352683, doi:10.1210/jc.2005-1536. Read September 2026.

What is still owed

3 figures are recorded in this site’s data without a published document behind them, out of 5 molecules. Each is printed on the page it belongs to with a visible marker rather than withheld or quietly rounded, and none of the three is a gap in the looking — one is a disagreement between three FDA labels, one is a status no document read states in those terms, and one is a half-life the human literature explicitly reports as never measured.

  • Tesamorelin, half-life: recorded as “26–38 min”.
  • Ipamorelin, fda status: recorded as “not approved”.
  • CJC-1295 (no DAC), half-life: recorded as “~30 min”.

⛔ None of them will be closed by picking the most plausible-looking reference. Corrections are published, dated and signed on the corrections page; how a figure gets read is on the editorial policy page.

Elena Marchetti writes about peptide therapeutics and drug development. Last reviewed September 2026.